Gossamer Bio, Inc. Loss Submission Form

The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS) who purchased common stock between February 8, 2019 and December 13, 2019 and/or who acquired Gossamer shares pursuant or traceable to Gossamer’s documents issued in connection with its February 8, 2019 initial public offering. The action, which was filed in the United States District Court for the Southern District of California, alleges that the Company violated federal securities laws.

In particular, the Gossamer lawsuit alleges that the Company failed to disclose: (1) the reasons for Gossamer’s GB001 trial failures; (2) the purported clinical validation of Novartis’ oral DP2 antagonist; and (3) that as a result of the foregoing, Defendants’ public statements were materially false and misleading at all relevant times.

Shareholders have until June 2, 2020 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.

To learn more and keep informed, complete this form >